GlassScriptPhysician profile
Shivani Sharma
NPI 1508342189
$1,040.82
in general payments reported to CMS, 2019-2025
21 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.56 · 2022: $104 · 2023: $128 · 2024: $491 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $907 · Debt Forgiveness: $17.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $907.39 |
| Debt Forgiveness | $17.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $223.66 | 2023-2025 | Vraylar |
| Lilly USA, LLC | $181.12 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Idorsia Pharmaceuticals US INC | $94.99 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.44 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $54.76 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Collegium Pharmaceutical, INC. | $52.62 | 2025 | Jornay Pm |
| Amgen INC. | $44.81 | 2024 | Evenity, Prolia, Repatha |
| Pfizer INC. | $38.68 | 2024 | |
| Neurocrine Biosciences, INC. | $36.23 | 2025 | |
| Valinor Pharma, LLC | $34.99 | 2024 | Movantik |
| Takeda Pharmaceuticals U.S.A., INC. | $34.90 | 2025 | Trintellix |
| Baxter Healthcare | $32.81 | 2022-2023 | |
| Corium, LLC | $26.37 | 2025 | Azstarys |
| Abbott Laboratories | $24.66 | 2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $20.19 | 2025 | Gemtesa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $15.94 | 2024 | |
| Exact Sciences Corporation | $13.88 | 2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $13.82 | 2024 | Airsupra |
| Phathom Pharmaceuticals, INC. | $13.24 | 2024 | Voquezna |
| Noven Therapeutics, LLC | $13.15 | 2024 | Xelstrym |
| Teva Pharmaceuticals USA, INC. | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shivani Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.